

04-15-2003

Form PTO-1595
(Rev. 10/02)4-8-03^{RL}102419473
PATENTS ONLYU.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

OMB No. 0651-0027 (exp. 6/30/2005)

Tab settings ⇌ ⇌ ⇌ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

CeNes Pharmaceuticals, Inc.

2. Name and address of receiving party(ies)

Name: Acorda Therapeutics, Inc.

Internal Address: _____

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:



Assignment



Merger



Security Agreement



Change of Name



Other _____

Street Address: 15 Skyline Drive

City: Hawthorne State: NY Zip: 10532

Execution Date: 2-28-03

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) See AttachedSchedule A AssignmentB. Patent No.(s) See AttachedSchedule A AssignmentAdditional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Mark Farber

Internal Address: _____

Street Address: 15 Skyline Drive

City: Hawthorne State: NY Zip: 10532

6. Total number of applications and patents involved: **31**

7. Total fee (37 CFR 3.41).....\$ 1,240.00



Enclosed



Authorized to be charged to deposit account

8. Deposit account number:

500-707

DO NOT USE THIS SPACE

9. Signature.

Mark Farber, Reg. No. 34,159

Name of Person Signing

Signature

March 21, 2003

Date

Total number of pages including cover sheet, attachments, and documents: **5**

04/14/2003 BYRNE 00000190 500707 5530109

01 FC:0021 1240.00 CH

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231**PATENT**
REEL: 013943 FRAME: 0249

SCHEDULE A

U.S. Patent No.	Issue Date	Title	Inventor(s)
5,530,109	06/25/1996	DNA ENCODING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
5,602,096	02/11/1997	METHOD OF USING A SECRETABLE GLIAL MITOGENIC FACTOR TO INDUCE ACETYLCHOLINE RECEPTOR SYNTHESIS	A. Goodearl et al.
6,147,190	11/14/2000	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,854,220	12/29/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,792,849	08/11/1998	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
5,621,081	04/15/1997	GLIAL MITOGENIC FACTORS	A. Goodearl et al.
5,606,032	02/25/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
6,232,286	05/15/2001	METHOD OF STIMULATING MITOGENESIS IN GLIAL CELLS USING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
6,194,377	02/27/2001	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
5,716,930	02/10/1998	GLIAL GROWTH FACTORS	A. Goodearl et al.
6,204,241	03/20/2001	METHODS FOR TREATING NERVOUS SYSTEM PATHOLOGIES USING GLIAL GROWTH FACTORS	A. Goodearl et al.
6,444,642	09/03/2002	METHODS OF INCREASING MYOTUBE FORMATION OR SURVIVAL OR MUSCLE CELL MITOGENESIS, DIFFERENTIATION OR SURVIVAL USING A NEUREGULIN	Robert Sklar et al.
5,594,114	01/14/1997	SCHWANN CELL MITOGENIC FACTOR, ITS PREPARATION AND USE	A. Goodearl et al.
6,087,323	07/11/2000	USE OF NEUREGULINS AS MODULATORS OF CELLULAR COMMUNICATION	David Gwynne et al.
5,876,973	03/02/1999	METHOD FOR MAKING ANTIBODIES WHICH SPECIFICALLY BIND TO GLIAL GROWTH FACTORS	David Gwynne et al.

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
08/471,833	06/06/1995	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/730,019	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/736,019	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,592	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/736,070	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/472,065	06/06/1995	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/735,010	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/469,549	06/06/1995	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,665	10/22/1996	GLIAL MITOGENIC FACTORS THEIR PREPARATION AND USE	A. Goodearl et al.

SCHEDULE A (Continued)

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
08/461,097	06/05/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/468,731	06/06/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/411,295	03/27/1995	METHODS FOR TREATING DISORDERS OF THE EYE	T.A. Reh ET AL.
09/069,784	03/20/2001	USE OF NEUREGULINS AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/366,886	08/04/1999	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/298,121	04/23/1999	METHODS FOR TREATING K. BIEKER-BRADY ET AL. CONGESTIVE HEART FAILURE	
09/530,884	10/18/1998	THERAPEUTICS METHODS COMPRISING USE OF A NEUREGULIN	R.N. MCBURNEY ET AL.

ASSIGNMENT OF INVENTION

In consideration of the payment by ASIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR: CeNeS Pharmaceuticals plc
Compass House, Vision Park
Chivers Way, Histon
Cambridge CB4 9ZR
UK

(If assignment is by person or entity to whom invention was previously assigned and this was recorded in PTO add the following)

Recorded on: _____

Reel: _____

Frame: _____

Hereby sell, assign and transfer to

ASSIGNEE: Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne, New York 10532
U.S.A.

And the successors, assigns and legal representatives of the ASIGNEE the entire right, title and interest, including the right to sue for present, past and future infringement, in the United States, its territorial possessions, and in all foreign countries, including all treaty and convention rights in and to the invention and any and all improvements of the patents and patent applications listed on Schedule A attached hereto;

And any legal equivalent thereof in a foreign country, and, in and to, all United States and foreign Letters Patent, for the full term thereof, to be obtained for said invention by the above application or any continuation, division, renewal, extension or substitute thereof, and as to letters patents any re-issue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all such Letters Patent to ASSIGNEE:


ASSIGNOR further covenants to promptly provide all pertinent facts and documents known and accessible to ASSIGNOR relating to said invention and said Letters Patent and legal equivalents; to testify as to the same in any interference, litigation or proceeding related thereof; to execute and deliver any and all papers that may be necessary or desirable to perfect the title to said invention or any Letters Patents which may be granted therefore in said ASSIGNEE, its

successors, assigns or other legal representatives; to execute any additional or divisional applications for patents for said invention or any part or parts thereof, and for the reissue of any Letters Patents to be granted therefore; and to make all rightful oaths and do all lawful acts requisite for procuring the same or for aiding therein, all without further compensation, but at the sole expense of ASSIGNEE, its successors, assigns, or other legal representatives.

ASSIGNORS hereby grants ASSIGNEE and Assignee's attorneys the power to insert the Serial No. and/or filing date of the above-described application(s) after such information becomes known to them.

IN WITNESS WHEREOF, I have hereunto set hand and seal.

ASSIGNOR:

A handwritten signature, possibly reading "N. A.", is written over a horizontal line.

Dated: 28-02-07

(Page 2 of 4)